This presentation covers:
- An overview of SARS-CoV-2 vaccine development
- Target antigens for vaccine development
- SARS-CoV-2 assays at IQVIA Laboratories
To learn more, download presentation slides or watch recorded presentation.
Related Insights
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
Vaccine Testing for SARS-CoV-2
ELISA and Viral Neutralization Assays
Keeping Up with the Flu: Advances in seasonal influenza vaccine development
Vaccine Laboratory Services
Combating Emerging and Re-Emerging Infectious Diseases in Clinical Trials by Harnessing Innovative Technologies
Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases
Tools for better management of infectious disease clinical trials
Zika Vaccine Research: Complex Steps Toward a Critical Need
Overcoming Zika vaccine development challenges
Vaccine Testing Capabilities
End-to-end laboratory for clinical vaccine development
